Fellow in interventional cardiology at Duke University, School of Medicine
As of 2011 · Last known relationship
J. Matthew Brennan is an interventional cardiologist and Associate Professor of Medicine at Duke University Medical Center, with clinical interests in coronary and valvular heart disease. His research centers on shared decision making in coronary heart disease and the use of statistical methods and study design for comparative-effectiveness analysis using large observational databases. He has served as Director of the Duke Analysis Center for the Transcatheter Valve Therapy CVT Registry and co-director of an analysis center for the Society of Thoracic Surgeons Database. His training includes an M.D. from the University of Mississippi, medicine residency at the University of Chicago, and cardiology and interventional cardiology fellowships at Duke. Earlier grants examined regulatory science, aortic-valve outcomes, statistical methods, and outcome ascertainment.
Each topic is linked to its supporting source in Sources.
Training includes Fellow in interventional cardiology at Duke University, School of Medicine, Fellowship in cardiology at Duke University, School of Medicine, Residency in medicine at The University of Chicago, and MD, plus 6 more records.
Explore education and trainingAs of 2011
As of 2010
As of 2006
Completed 2003
Ablation of atrial fibrillation during coronary artery bypass grafting: Late outcomes in a Medicare population[7]
2021
Administrative Claims-based Efficiencies for the Advancement of Regulatory Sciences, awarded by Burroughs Wellcome Fund[7]
2014 to 2021
Association Between Patient Survival and Clinician Variability in Treatment Rates for Aortic Valve Stenosis[7]
2021
Association of postoperative complications and outcomes following coronary artery bypass grafting[7]
2020
Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials[7]
2019
Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry[7]
2019
Defining the scale of undertreatment of aortic valve stenosis in the United States and raising awareness of the issue[8]
Efficiencies for Outcome Ascertainment throughout the Total Product Life Cycle, awarded by Food and Drug Administration[7]
2012 to 2017
Optimizing Health Outcomes in Patients with Symptomatic Aortic Valve Disease, awarded by Patient-Centered Outcomes Research Institute[7]
2014 to 2020
Racial Differences in the Use of Aortic Valve Replacement for Treatment of Symptomatic Severe Aortic Valve Stenosis in the Transcatheter Aortic Valve Replacement Era[7]
2020
Reoperation After Transcatheter Aortic Valve Replacement: An Analysis of the Society of Thoracic Surgeons Database[7]
2020
Reply: Redo SAVR After Primary TAVR, A Dangerous Sequence?[7]
2020
Sex disparities in patients with symptomatic severe aortic stenosis[7]
2021
Shared decision making, particularly as it relates to coronary heart disease[8]
Statistical Methods for Complex Data in Cardiovascular Disease, awarded by North Carolina State University[7]
2013 to 2018
The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2019 Update on Research[7]
2019
Use of statistical techniques and study design for comparative effectiveness analysis using large randomized observational databases[8]